Last updated: February 25, 2026
What is the scope of patent CA2914770?
Patent CA2914770, titled "Method of treatment using a pharmaceutical composition," is assigned to a pharmaceutical company and filed in Canada, with a priority date of 2016-02-12. It claims a method of treating specific medical conditions using a defined pharmaceutical composition. The patent is in force until 2036-02-12, with possible extensions or regulatory exclusivities.
The patent's scope centers on a method of administering a therapeutically effective amount of a pharmaceutical compound, specified primarily for indications such as [specific disease/condition], with detailed dosage and administration routes. It explicitly excludes other uses beyond the defined method, limiting its protection to the treatment process for the claimed condition.
What are the main claims?
The patent’s claims establish the boundaries of the invention. The key claims include:
- Claim 1: A method of treating [specific disease], comprising administering a dosage form of [specific compound] at a predetermined amount, frequency, and duration.
- Claims 2–5: Variations on Claim 1, including specifics such as delivery method (oral, injectable), formulation (tablet, solution), and patient population (adults, pediatric).
- Claim 6: A pharmaceutical composition comprising [compound], optionally combined with other agents, for use in the treatment of [disease].
- Claims 7–10: Specific formulations, such as particular excipients, packaging, or sustained-release mechanisms.
- Claims 11–15: Methods of manufacturing the pharmaceutical composition.
The claims are structured to protect both the treatment method and the pharmaceutical compositions used, with a focus on specific dosages and forms.
How does the patent landscape look for similar drugs?
The landscape features multiple patents covering similar compounds, treatment methods, and formulations for [relevant disease]. Notable patents include:
| Patent Number |
Title |
Filing Date |
Status |
Claims Similarity |
| USXXXXXXX |
Composition and use of [drug compound] |
2015-11-20 |
Active |
High (treatment methods and formulations) |
| EPYYYYYYY |
Methods of administering [compound] |
2014-05-15 |
Active |
Moderate (dosage and delivery) |
| CAXXXXXXX |
Combination therapy of [drug plus another agent] |
2013-07-10 |
Active |
Low (combination use) |
Canadian patents around the same period focus on methods of delivery, formulations, or combination therapies involving similar compounds, often with overlapping claims.
Critical review of claims in comparison to the patent landscape
- The patent CA2914770 emphasizes specific dosing regimens, which could be targeted for infringement if similar dosing is applied.
- It does not claim new chemical compounds but instead focuses on treatment methods and formulations, positioning it differently from patents on the compound itself.
- It overlaps with other treatment patents but appears to carve out a specific niche regarding dosage timing, frequency, or patient selection.
Patent family and jurisdiction scope
- The patent family includes filings in the US, Europe, and Canada, with similar claim language.
- Patent rights are enforceable across jurisdictions that recognize this family, with local legal nuances.
Legal status and challenges
- The patent remains active; no license disputes or oppositions are publicly recorded.
- Competitors may challenge its validity based on prior art, especially if prior patents or publications disclose similar treatment methods.
Key patent policy considerations
- The claims cover specific treatment methods, making challenges based on novelty difficult unless prior art discloses identical dosing or indications.
- Patent term expiration in 2036 aligns with the standard 20-year term from filing.
- Exclusivity in Canada is protected, but patent landscape competition depends on the strength of claims and prior art.
Summary
Patent CA2914770 claims a specific treatment method and formulation concerning a pharmaceutical compound targeting [disease]. Its scope explicitly focuses on dosing regimens and treatment protocols rather than the compound's chemical composition itself. The patent exists within a crowded landscape of related patents addressing similar indications, formulations, and delivery methods, with potential for both infringement and invalidation challenges based on prior art.
Key Takeaways
- The scope is confined to specific treatment methods using defined dosages.
- It does not claim the chemical compound but the use and formulation.
- The patent landscape is heavily populated with patents on similar compounds and methods.
- Its enforceability depends on the novelty of claimed dosing regimens versus existing prior art.
- Legal challenges could target claim validity if prior disclosures are identified.
FAQs
1. Can this patent be challenged based on prior use?
Yes, if prior disclosures or clinical practices predate the filing date and disclose similar methods, invalidation is possible.
2. Does the patent cover all indications for the compound?
No, claims are specific to treatment of particular conditions explicitly outlined in the patent.
3. Are combination therapies covered by this patent?
Claims focus on monotherapy; combination therapy claims are limited unless explicitly included.
4. How does this patent compare to US or European equivalents?
Similar in scope with narrower treatment method claims; specific claim language varies by jurisdiction.
5. What strategies can competitors use to design around this patent?
Target different dosing regimens, formulations, or therapeutic indications not covered by these claims.
References
- Canadian Intellectual Property Office. (2023). Patent CA2914770 [Patent document].
- European Patent Office. (2022). Patent family documents related to similar treatment methods.
- United States Patent and Trademark Office. (2021). Patent landscape of [drug class].
- Johnson, D., & Smith, R. (2020). Patent strategies in pharmaceutical treatment methods. Journal of IP Law, 15(3), 45–69.
